SavedAdd your journal

Journals / Sağlık Bilimlerinde İleri Araştırmalar Dergisi / 2020 / Cilt: 3 - Sayı: 3

PTEN and AKT1 Gene Expression Levels in Childhood T-ALL Patients

Çocukluk Çağı T-ALL Hastalarında PTEN ve AKT1 Gen Anlatım Düzeyleri

Fulya KÜÇÜKCANKURT
Özden HATIRNAZ NG
Müge SAYİTOĞLU
Yücel ERBİLGİN
Pages
114–121
Publication Date
2020-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no significant relationship between gene expression and clinical features of the patients, overall and disease-free survival rates while induction therapy-related survival analyzes revealed a significant relationship between PTEN and AKT1 gene expression and overall survival rates (p=0.026 and p=0.034 Cox regression analysis, respectively).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Impaired activation of the PI3K/AKT signaling pathway has been associated with tumor development.
📊
Key Findings & Data:In this study, PTEN and AKT1 gene expression were determined in childhood T-ALL patients, and the effect was investigated on the prognosis of the disease.
💡
Conclusion & Impact:There was no significant relationship between gene expression and clinical features of the patients, overall and disease-free survival rates while induction therapy-related survival analyzes revealed a significant relationship between PTEN and AKT1 gene expression and overall survival rates (p=0.026 and p=0.034 Cox regression analysis, respectively).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:T-hücreli Akut Lenfoblastik Lösemi · Gen Anlatımı · PTEN

Abstract

Objective: Impaired activation of the PI3K/AKT signaling pathway has been associated with tumor development. The PTEN/AKT pathway plays a critical role in cell growth and survival and has been associated with chemotherapy resistance in leukemia. In this study, PTEN and AKT1 gene expression were determined in childhood T-ALL patients, and the effect was investigated on the prognosis of the disease. Materials and Methods: Bone marrow samples from 39 childhood cases were obtained at the time of diagnosis and screened with real-time quantitative PCR for PTEN and AKT1 genes. Results: In our study, no difference between T-ALL patients compared to controls was observed in PTEN gene expression whereas AKT1 gene expression was significantly increased (p<0.0001). There was no significant relationship between gene expression and clinical features of the patients, overall and disease-free survival rates while induction therapy-related survival analyzes revealed a significant relationship between PTEN and AKT1 gene expression and overall survival rates (p=0.026 and p=0.034 Cox regression analysis, respectively). Conclusion: In our study, the presence of increased AKT1 gene expression was demonstrated in T-ALL patients independent of PTEN expression. Future studies will reveal whether it will be a suitable candidate for targeted therapies.

Özet

Amaç: PI3K/AKT sinyal yolağının bozulmuş aktivasyonu tümör gelişimi ile ilişkilendirilmiştir. PTEN/AKT yolağı, hücre büyümesi ve sağ kalımında kritik role sahip olup, lösemilerde kemoterapi direnci ile ilişkilendirilmiştir. Bu çalışma kapsamında, çocukluk çağı T-ALL hastalarındaki PTEN ve AKT1 gen anlatımları belirlendi ve hastalığın prognozuna olan etkisi araştırıldı. Gereç ve Yöntem: Otuz dokuz çocukluk çağı T-ALL olgusunun, tanı zamanı kemik iliği örnekleri kantitatif gerçek zamanlı PZR ile PTEN ve AKT1 genleri için tarandı. Gen anlatım düzeylerinin hastaların yaş, cinsiyet, immünfenotip, tedavi yanıtı, nüks ve sağ kalım gibi klinik verileri ile ilişkisi incelendi. Bulgular: Çalışmamızda, T-ALL hastalarında PTEN gen anlatımında kontrollere göre bir farklılık gözlenmezken, AKT1 gen anlatımının anlamlı düzeyde arttığı belirlendi (p<0,0001). Hastaların klinik özellikleri, genel ve hastalıksız sağ kalım oranları ve gen anlatım düzeyleri arasında anlamlı bir ilişki saptanmazken, indüksiyon tedavi ilişkili sağ kalım analizleri PTEN ve AKT1 gen anlatımları ile genel sağ kalım oranları arasında (sırasıyla, p=0,026 ve p=0,034 Cox regresyon analizi) anlamlı bir ilişki ortaya koyuldu. Diğer klinik parametreler ile gen anlatım düzeyleri arasında anlamlı ilişki saptanmadı. Sonuç: Çalışmamızda, T-ALL örneklerinde PTEN gen anlatımından bağımsız olarak artmış AKT1 gen anlatımının varlığı ve sağ kalım sürelerini etkilediğine dair bulgular elde edildi. Gelecekteki çalışmalar, AKT1’in hedefe yönelik tedaviler için uygun bir aday olup olmayacağını ortaya çıkaracaktır.

🔖

Cite This Article

KÜÇÜKCANKURT, F., NG, Ö. H., SAYİTOĞLU, M., ERBİLGİN, Y. (2020). PTEN and AKT1 Gene Expression Levels in Childhood T-ALL Patients. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, Cilt: 3 - Sayı: 3, 114–121. https://ajindex.com/articles/217127

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211–8
  2. Ferrando A. Can one target T-cell ALL? Best Pract Rese. Clin Haematol. 2018;31(4);361–6
  3. Okumura N, Yoshida H, Kitagishi Y, Murakami M, Nishimura Y, Matsuda S. PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis. Advances in Hematology. 2012
  4. Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2016;67:11–28
  5. Worby CA, Dixon JE. PTEN. Annu Rev Biochem. 2014; 83(1):641–69
  6. Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N et al. PTEN: Multiple functions in human malignant tumors. Front Oncol. 2015;16(5):24
  7. Wickremasinghe RG, Prentice AG, Steele AJ. Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets. Br J Haematol. 2011;153(5):545–56
  8. Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125(20):4687–92
  9. Chalhoub N, Baker SJ. PTEN and the PI3- kinase pathway in cancer. Annu Rev Pathol. 2009;4:127–50
  10. Kharas GM, Okabe R, JJ. Ganis, Gozo M, Khandan T, Paktinat M, Gilliland GD et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 2010;115(7):1406–15
  11. Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y et al. The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta- Analysis. Oncologist. 2014;19(5):528–35
  12. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira S-M, Garcia-Echeverria C et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci. 2009;106(1):268–73
  13. Panuzzo C, Crivellaro S, Carrà G, Guerrasio A, Saglio G, Morotti A. BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. PloS One. 2014;9(10):e110682
  14. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM et al. Mutation of Pten/ Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96(4):1563–8
  15. Philip C-A, Laskov I, Beauchamp M-C, Marques M, Amin O, Bitharas J et al. Inhibition of PI3KAKT- mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017;17(1):638
  16. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, Bose S. PTEN p